JP2014503589A - 組合せ - Google Patents

組合せ Download PDF

Info

Publication number
JP2014503589A
JP2014503589A JP2013551318A JP2013551318A JP2014503589A JP 2014503589 A JP2014503589 A JP 2014503589A JP 2013551318 A JP2013551318 A JP 2013551318A JP 2013551318 A JP2013551318 A JP 2013551318A JP 2014503589 A JP2014503589 A JP 2014503589A
Authority
JP
Japan
Prior art keywords
amino
compound
pharmaceutically acceptable
combination
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013551318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503589A5 (enExample
Inventor
クルト、アール．オージェ
ジャスティン、ボッツフォード‐ミラー
アニル、ケイ．スッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2014503589A publication Critical patent/JP2014503589A/ja
Publication of JP2014503589A5 publication Critical patent/JP2014503589A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013551318A 2011-01-26 2012-01-26 組合せ Pending JP2014503589A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161436435P 2011-01-26 2011-01-26
US61/436,435 2011-01-26
PCT/US2012/022638 WO2012103276A1 (en) 2011-01-26 2012-01-26 Combinations

Publications (2)

Publication Number Publication Date
JP2014503589A true JP2014503589A (ja) 2014-02-13
JP2014503589A5 JP2014503589A5 (enExample) 2015-03-19

Family

ID=46581159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013551318A Pending JP2014503589A (ja) 2011-01-26 2012-01-26 組合せ

Country Status (13)

Country Link
US (2) US20130296356A1 (enExample)
EP (1) EP2667871A4 (enExample)
JP (1) JP2014503589A (enExample)
KR (1) KR20140011322A (enExample)
CN (1) CN103476413B (enExample)
AU (1) AU2012209100A1 (enExample)
BR (1) BR112013018565A2 (enExample)
CA (1) CA2825790A1 (enExample)
EA (1) EA201391076A1 (enExample)
IL (1) IL227377A0 (enExample)
MX (1) MX2013008654A (enExample)
SG (1) SG191926A1 (enExample)
WO (1) WO2012103276A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404888SA (en) * 2012-02-17 2014-09-26 Pharmacyclics Inc Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
IN2015DN02667A (enExample) * 2012-10-12 2015-09-04 Glaxosmithkline Llc
AU2013334945A1 (en) * 2012-10-22 2015-04-23 Novartis Ag Combination
US20150306099A1 (en) * 2012-11-27 2015-10-29 Glaxosmithkline Llc Combination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062578A1 (en) * 2008-10-27 2010-06-03 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034860B2 (en) * 2006-07-21 2011-10-11 Eastman Specialties Holdings Corporation Organosol plastisol compositions
EP2727909A1 (en) * 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
WO2010036796A1 (en) * 2008-09-26 2010-04-01 Concert Pharmaceuticals, Inc. Pyridineamine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062578A1 (en) * 2008-10-27 2010-06-03 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak

Also Published As

Publication number Publication date
CN103476413A (zh) 2013-12-25
KR20140011322A (ko) 2014-01-28
US20130296356A1 (en) 2013-11-07
CA2825790A1 (en) 2012-08-02
IL227377A0 (en) 2013-09-30
EP2667871A1 (en) 2013-12-04
EP2667871A4 (en) 2014-07-09
US20160067248A1 (en) 2016-03-10
BR112013018565A2 (pt) 2016-09-27
CN103476413B (zh) 2016-03-16
AU2012209100A1 (en) 2013-08-01
MX2013008654A (es) 2013-09-02
SG191926A1 (en) 2013-08-30
EA201391076A1 (ru) 2014-07-30
WO2012103276A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
Takebe et al. Targeting notch signaling pathway in cancer: clinical development advances and challenges
US20140051662A1 (en) Treatment of multiple myeloma with masitinib
JP5903433B2 (ja) 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
JP2008514577A (ja) Ｚｄ６４７４及びイマチニブを含んでなる組合せ
JP2020169222A (ja) 癌を治療するための方法
US20160067248A1 (en) Combinations
JP6546098B2 (ja) 組み合わせ処置
TW202131917A (zh) 併用醫藥
JP2015533165A (ja) 組み合わせ
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
KR101924801B1 (ko) 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
WO2014002922A1 (ja) 抗癌剤の併用による癌治療方法
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
WO2021018310A1 (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
US20170027938A1 (en) Combination
RU2845210C1 (ru) Фармацевтическая композиция, включающая ингибитор протеинкиназы и химиотерапевтическое средство, и ее применение
JP6013359B2 (ja) 組合せ
JP2013526613A (ja) 組合せ
TW201605449A (zh) 馬賽替尼治療結腸直腸癌的用途
JP2015163592A (ja) 抗癌剤の併用による癌治療方法
HK40050227A (en) Cancer combination therapy using quinoline carboxamide derivative
JP2015534987A (ja) 組合せ
WO2011152515A1 (ja) インドール化合物を含有する抗腫瘍剤
JP2015163591A (ja) 抗癌剤の併用による癌治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160513